Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Lorcaserin

Stage Phase 1/2Stale

Sponsor Novo Nordisk A/S

Route oral and injection

Class Serotonin agonist

Mechanism selective serotonin agonist

Sources

registry, as of 2017-06-06Stale

https://clinicaltrials.gov/study/NCT03799198

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity. Overall status COMPLETED. Phases PHASE4. Lead sponsor Novo Nordisk A/S. Enrollment 200. Conditions Obesity. Researchers are doing this study to compare the effects of drugs approved for long-term weight loss combined with an employer-based weight management program with the effects of the weight management program without drugs for weight loss. If participants agree to be in this study

ClinicalTrials.gov NCT03799198 protocol and results modules

registry, as of 2024-03-27Stale

https://clinicaltrials.gov/study/NCT03353220

Predictors of Lorcaserin-Induced Weight Loss. Overall status TERMINATED. Phases PHASE4. Lead sponsor Columbia University. Enrollment 32. Conditions Overweight and Obesity. This two-phase study aims to explore ways to predict who will respond well to the weight loss drug lorcaserin and to understand the mechanisms that develop which limit drug efficacy. Subjects will be recruited for a 5-week crossover study (phase 1) with lorcaserin and placebo fol

ClinicalTrials.gov NCT03353220 protocol and results modules

registry, as of 2018-06-11Stale

https://clinicaltrials.gov/study/NCT02388568

Lifestyle Modification and Lorcaserin for Weight Loss Maintenance. Overall status COMPLETED. Phases NA. Lead sponsor University of Pennsylvania. Enrollment 137. Conditions Obesity. The proposed 12-month randomized controlled trial will assess the efficacy of lifestyle counseling, combined with lorcaserin (10 mg BID) or placebo, in maintaining weight loss achieved during a prior 14-week dietary run-in. 14-week run-in. To qualify for randomization, participa

ClinicalTrials.gov NCT02388568 protocol and results modules

registry, as of 2019-10-31Stale

https://clinicaltrials.gov/study/NCT03552107

Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic. Overall status COMPLETED. Phases not stated. Lead sponsor Scripps Whittier Diabetes Institute. Enrollment 157. Conditions Obesity; Weight Loss; Overweight. This is a retrospective, descriptive study that involves de-identified data consisting of weight changes, pertinent vital signs and laboratory values influenced by body weight, and healthcare utilization of patients prescribed lorcaserin at The Center for Weight Management at the

ClinicalTrials.gov NCT03552107 protocol and results modules

registry, as of 2019-07-16Stale

https://clinicaltrials.gov/study/NCT02019264

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors. Overall status COMPLETED. Phases PHASE4. Lead sponsor Eisai Inc.. Enrollment 14673. Conditions Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes. This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.

ClinicalTrials.gov NCT02019264 protocol and results modules

registry, as of 2017-06-06Stale

https://clinicaltrials.gov/study/NCT02393547

Lorcaserin for Preventing Weight Gain Among Smokers. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Mayo Clinic. Enrollment 20. Conditions Tobacco Use Disorder; Weight Gain. This will be an open label clinical trial with all subjects receiving both lorcaserin and varenicline with a primary aim of reducing post cessation weight gain.

ClinicalTrials.gov NCT02393547 protocol and results modules

publication, as of 2012-06-05Stale

https://pubmed.ncbi.nlm.nih.gov/31644141/

Lorcaserin is a selective serotonin agonist that was used as a weight loss agent. Lorcaserin was in clinical use for eight years when it was withdrawn because of concerns regarding an excess in cancer risk after long term u

PMID 31644141

Studies

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

Registry NCT03799198

Phase Phase 4

Status Completed

Enrollment 200

Start 2019-01-07

Primary completion 2020-05-22

Study completion 2020-05-22

WMP + Rx

Regimen once monthly

Population Obesity

WMP alone

Regimen once monthly

Population Obesity

Predictors of Lorcaserin-Induced Weight Loss

Registry NCT03353220

Phase Phase 4

Status Terminated

Enrollment 32

Start 2018-01-03

Primary completion 2020-02-14

Study completion 2020-02-14

Arm A

Population Overweight and Obesity

Arm B

Population Overweight and Obesity

Lifestyle Modification and Lorcaserin for Weight Loss Maintenance

Registry NCT02388568

Phase Not applicable

Status Completed

Enrollment 137

Lorcaserin plus Lifestyle Modification

Regimen weekly

Weeks 8

Comparator placebo

Population Obesity

Placebo plus Lifestyle Modification

Regimen weekly

Weeks 8

Population Obesity

Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic

Registry NCT03552107

Status Completed

Enrollment 157

Start 2017-04-11

Primary completion 2018-10-11

Study completion 2019-04-11

Observational Group - Lorcaserin Treated

Population Obesity; Weight Loss; Overweight

CAMELLIA-TIMI

Registry NCT02019264

EudraCT 2013-000324-34

Phase Phase 4

Status Completed

Enrollment 14673

Start 2014-01-24

Primary completion 2018-05-14

Study completion 2018-05-14

Lorcaserin hydrochloride (HCL)10 mg

Dose 10 mg

Regimen twice daily

Comparator placebo

Population Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes

Placebo

Regimen twice daily

Population Cardiovascular Disease; High Cardiovascular Risk; Obesity; Overweight; Type 2 Diabetes

Lorcaserin for Preventing Weight Gain Among Smokers

Registry NCT02393547

Phase Phase 1/2

Status Completed

Enrollment 20

Varenicline + Lorcaserin

Population Tobacco Use Disorder; Weight Gain